-0.780 (-1.99%)
Range 37.110 - 44.850   (20.86%)
Open 41.260
Previous Close 39.230
Buy Price 2.310
Buy Volume -
Sell Price 2.320
Sell Volume -
Volume 5,689,433
Value -
Measurement Type Value
EPS (USD) -0.038
Trailing EPS (USD) -0.038
NAV (USD) 0.007
Cash In Hand (USD) 0.007
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5,267.123
Price / Cash In Hand 5,738.806
Issued & Paid-up Shares 41,562,100
Treasury Shares 5,000
Market Cap (M) 4,452.664
Par Value (USD) n.a.
Beta - 75 Days -
R-Squared - 75 Days(%) -
Beta - 500 Days -
R-Squared - 500 Days(%) -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 08 May 2021 04:00.
Data powered by
View All Events


BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company's pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient's own somatic or adult stem cells, at the desired location.

Loading Chart...